Evidence map›Paper›PMID 41291709›Full record

ArticleWorld journal of surgical oncology2025

Development and validation of a nomogram model for predicting acute hepatic dysfunction post-intervention in primary hepatocellular carcinoma: a retrospective case-control study.

Lu Xu, Linan Du, Jianhua Pan, Xiang Xie

Abstract readValidation Study
In one paragraph

Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lu XuDepartment of Interventional Therapy, The Second Affiliated Hospital of Anhui Medical University, No. 678, Furong Road, Shushan District, Hefei, 230601, China.
Linan DuDepartment of Interventional Therapy, The Second Affiliated Hospital of Anhui Medical University, No. 678, Furong Road, Shushan District, Hefei, 230601, China.
Jianhua PanDepartment of Interventional Therapy, The Second Affiliated Hospital of Anhui Medical University, No. 678, Furong Road, Shushan District, Hefei, 230601, China.
Xiang XieDepartment of Interventional Therapy, The Second Affiliated Hospital of Anhui Medical University, No. 678, Furong Road, Shushan District, Hefei, 230601, China. ayefyjrk@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo identify independent risk factors for acute liver function damage (ALFD) following interventional treatment in hepatocellular carcinoma (HCC) patients and to develop and validate a novel Nomogram predictive model.

methodsA retrospective analysis of 362 HCC patients diagnosed from January 2021 to October 2023 was conducted, dividing them into a training set (n = 253) and an internal validation set (n = 109) using the bootstrap method. Significant factors were first screened through univariate analysis and the Least Absolute Shrinkage and Selection Operator (LASSO) method, followed by Logistic regression to determine independent risk factors. A Nomogram was constructed using R language, with its discriminative ability and consistency assessed by the area under the ROC curve (AUC) and calibration plots, and its clinical utility evaluated through decision curve analysis (DCA).

resultsThree independent influencing factors were identified from the multivariate logistic regression analysis of the training set: Child-Pugh (OR: 0.34, 95%CI:0.21-0.52, P < 0.001), APRI (OR: 3.47,95%CI:2.07-6.51,P < 0.001), and FIB-4 (OR: 1.30, 95%CI:1.16-1.47, P < 0.001), which were included in the Nomogram. This Nomogram predicted an AUC value for ALFD post-TACE in HCC patients of 0.900 in the training set and 0.854 in the internal validation set. Calibration curves also demonstrated that the nomogram's predictions were close to the ideal curve, with predictions consistent with actual outcomes, and the DCA curve showed benefits for all patients. These conclusions were also confirmed in the validation set.

conclusionThe newly developed Nomogram provides a highly predictive tool for risk assessment of ALFD post-TACE in HCC patients, serving as a potent instrument for personalized diagnosis and treatment.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsNomogramsAdultAgedCase-Control StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsROC CurveAcute liver function deteriorationHepatocellular carcinomaInfluencing factorsInterventional treatmentLASSO regressionNomogram

Identifiers

PMID41291709
PMCPMC12649006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.